TBPH offering history
Every offering-related filing in Theravance Biopharma, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 1,000 filings back to May 7, 2015.
| Date | Filing | What it means | |
|---|---|---|---|
| Jun 25, 2021 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jun 24, 2021 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Sep 1, 2020 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Feb 12, 2020 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Feb 10, 2020 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Dec 3, 2019 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Oct 31, 2016 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Oct 31, 2016 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Oct 28, 2016 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Oct 26, 2016 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Oct 26, 2016 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Oct 26, 2016 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Apr 29, 2016 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Apr 29, 2016 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Apr 27, 2016 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Mar 14, 2016 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Oct 26, 2015 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jul 16, 2015 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jul 9, 2015 | S-3/A → | REGISTERED | S-3/A registration — capacity to sell shares, not a sale yet |
| Jun 26, 2015 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
TBPH offering FAQ
When did TBPH last execute an offering?
Per SEC filings, Theravance Biopharma, Inc.'s most recent priced offering document is a 424B5 filed 2021-06-25. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did TBPH last announce or register an offering?
The most recent registration is a S-3ASR filed 2020-09-01. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.